JP2018520117A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520117A5 JP2018520117A5 JP2017561821A JP2017561821A JP2018520117A5 JP 2018520117 A5 JP2018520117 A5 JP 2018520117A5 JP 2017561821 A JP2017561821 A JP 2017561821A JP 2017561821 A JP2017561821 A JP 2017561821A JP 2018520117 A5 JP2018520117 A5 JP 2018520117A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- composition according
- composition
- mutation
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000035772 mutation Effects 0.000 claims description 26
- 201000005787 hematologic cancer Diseases 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 17
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 15
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 10
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 6
- 102100023884 Probable ribonuclease ZC3H12D Human genes 0.000 claims description 6
- 201000003444 follicular lymphoma Diseases 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 4
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 102000013968 STAT6 Transcription Factor Human genes 0.000 claims description 4
- 108010011005 STAT6 Transcription Factor Proteins 0.000 claims description 4
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 229960001507 ibrutinib Drugs 0.000 claims description 4
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000012664 BCL-2-inhibitor Substances 0.000 claims description 2
- 229940124291 BTK inhibitor Drugs 0.000 claims description 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims description 2
- 102100026008 Breakpoint cluster region protein Human genes 0.000 claims description 2
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 claims description 2
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102000005650 Notch Receptors Human genes 0.000 claims description 2
- 108010070047 Notch Receptors Proteins 0.000 claims description 2
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims description 2
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 25
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 description 25
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021108659A JP2021152076A (ja) | 2015-05-29 | 2021-06-30 | Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168530P | 2015-05-29 | 2015-05-29 | |
| US62/168,530 | 2015-05-29 | ||
| US201562263582P | 2015-12-04 | 2015-12-04 | |
| US62/263,582 | 2015-12-04 | ||
| PCT/US2016/034861 WO2016196385A1 (en) | 2015-05-29 | 2016-05-27 | Cerdulatinib for the treatment of b-cell malignancies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021108659A Division JP2021152076A (ja) | 2015-05-29 | 2021-06-30 | Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520117A JP2018520117A (ja) | 2018-07-26 |
| JP2018520117A5 true JP2018520117A5 (enExample) | 2019-06-20 |
| JP7258462B2 JP7258462B2 (ja) | 2023-04-17 |
Family
ID=57441822
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017561821A Active JP7258462B2 (ja) | 2015-05-29 | 2016-05-27 | Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ |
| JP2021108659A Pending JP2021152076A (ja) | 2015-05-29 | 2021-06-30 | Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021108659A Pending JP2021152076A (ja) | 2015-05-29 | 2021-06-30 | Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20180147203A1 (enExample) |
| EP (1) | EP3302485B1 (enExample) |
| JP (2) | JP7258462B2 (enExample) |
| KR (1) | KR102613106B1 (enExample) |
| CN (1) | CN107683139A (enExample) |
| AU (1) | AU2016270658B2 (enExample) |
| CA (1) | CA2987324C (enExample) |
| ES (1) | ES2958412T3 (enExample) |
| WO (1) | WO2016196385A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170042896A1 (en) | 2015-08-12 | 2017-02-16 | Portola Pharmaceuticals, Inc. | Cerdulatinib for treating myeloma |
| CN108367006B (zh) | 2015-12-04 | 2021-12-31 | 博尔托拉制药公司 | 用于治疗血液癌症的赛度替尼 |
| US20180065317A1 (en) | 2016-09-06 | 2018-03-08 | Cc3D Llc | Additive manufacturing system having in-situ fiber splicing |
| WO2018189566A1 (en) * | 2017-04-10 | 2018-10-18 | Dorian Bevec | Use of a chemical compound as a therapeutic agent |
| CN112074271B (zh) * | 2018-05-04 | 2023-10-20 | 博尔托拉制药公司 | 用于治疗淋巴瘤的方法 |
| JP7324778B2 (ja) | 2018-05-04 | 2023-08-10 | ポートラ ファーマシューティカルズ， エルエルシー | セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態 |
| TWI805751B (zh) | 2018-05-04 | 2023-06-21 | 美商普托拉製藥有限公司 | 賽度替尼(cerdulatinib)之合成 |
| CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60255756A (ja) | 1984-06-01 | 1985-12-17 | Ikeda Mohandou:Kk | アミノアルキルフエノキシ誘導体 |
| WO1995032963A1 (en) | 1994-06-01 | 1995-12-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienylazole compound and thienotriazolodiazepine compound |
| WO1999031073A1 (en) | 1997-12-15 | 1999-06-24 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
| WO2003037352A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| CN1665789A (zh) | 2002-06-28 | 2005-09-07 | 山之内制药株式会社 | 二氨基嘧啶酰胺衍生物 |
| WO2008009458A1 (en) | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| CA2960692C (en) | 2008-04-16 | 2019-09-24 | Portola Pharmaceuticals, Inc. | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US8367689B2 (en) | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
| WO2012045010A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combinations of 4-(3-(2h-1,2,3-triazo-2-yl) phenylamino)-2-((1r,2s)-2-aminocyclohexylamino) pyrimidine-5-carboxamide and fludarabine |
| HK1198579A1 (en) * | 2011-08-10 | 2015-04-30 | Novartis Pharma Ag | Jak p13k/mtor combination therapy |
| CA2877903A1 (en) * | 2012-06-27 | 2014-01-03 | Novomer, Inc. | Catalysts and methods for polyester production |
| WO2014018567A1 (en) * | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| CA2890111A1 (en) | 2012-11-02 | 2014-05-08 | Pharmacyclics, Inc. | Tec family kinase inhibitor adjuvant therapy |
| CN105282602A (zh) * | 2014-07-07 | 2016-01-27 | 乐视致新电子科技（天津）有限公司 | 数据处理方法、装置及移动终端设备 |
| WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| US20170042896A1 (en) | 2015-08-12 | 2017-02-16 | Portola Pharmaceuticals, Inc. | Cerdulatinib for treating myeloma |
| CN108367006B (zh) * | 2015-12-04 | 2021-12-31 | 博尔托拉制药公司 | 用于治疗血液癌症的赛度替尼 |
-
2016
- 2016-05-27 EP EP16804177.0A patent/EP3302485B1/en active Active
- 2016-05-27 WO PCT/US2016/034861 patent/WO2016196385A1/en not_active Ceased
- 2016-05-27 CA CA2987324A patent/CA2987324C/en active Active
- 2016-05-27 KR KR1020177036772A patent/KR102613106B1/ko active Active
- 2016-05-27 US US15/578,190 patent/US20180147203A1/en not_active Abandoned
- 2016-05-27 JP JP2017561821A patent/JP7258462B2/ja active Active
- 2016-05-27 CN CN201680035029.0A patent/CN107683139A/zh active Pending
- 2016-05-27 ES ES16804177T patent/ES2958412T3/es active Active
- 2016-05-27 AU AU2016270658A patent/AU2016270658B2/en active Active
-
2021
- 2021-05-10 US US17/316,530 patent/US12350269B2/en active Active
- 2021-06-30 JP JP2021108659A patent/JP2021152076A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520117A5 (enExample) | ||
| de Claro et al. | FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia | |
| Moskowitz et al. | Targeting histone deacetylases in T-cell lymphoma | |
| Matuszkiewicz-Rowinska et al. | Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress | |
| Kang et al. | Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy | |
| Luo et al. | Cisplatin facilitates radiation-induced abscopal effects in conjunction with PD-1 checkpoint blockade through CXCR3/CXCL10-mediated T-cell recruitment | |
| Knipstein et al. | Entinostat for treatment of solid tumors and hematologic malignancies | |
| Cartei et al. | Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged | |
| JP2018535996A5 (enExample) | ||
| JP2020510704A5 (enExample) | ||
| Ghosh et al. | Expanding role of lenalidomide in hematologic malignancies | |
| Shen et al. | HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma | |
| CN108883109A (zh) | 用于治疗急性髓性白血病的联合疗法 | |
| O'Connor et al. | Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes | |
| Johnson‐Ansah et al. | Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia | |
| EP2501385A1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| Campbell et al. | Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid | |
| JP2020517704A5 (enExample) | ||
| Anderson et al. | Fludarabine: a review of its use in non-Hodgkin’s lymphoma | |
| JPH07506804A (ja) | 痴呆の処置のためのダプソーン及びプロミン | |
| Rajendra et al. | Venetoclax: A narrative drug review | |
| Steinemann et al. | Activity of nintedanib in germ cell tumors | |
| Laribi et al. | Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine | |
| Yamamoto et al. | Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer | |
| Licun et al. | Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy |